Immunogen Earnings: Here’s Why These Results aren’t Pleasing Shareholders

Immunogen Inc. (NASDAQ:IMGN) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 4.36%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Immunogen Inc. Earnings Cheat Sheet

Results: Net loss increased 91.37% to $24.4 million (29 cents per diluted share) in the quarter versus a net loss of $12.75 million in the year-earlier quarter.

Revenue: Decreased 65.88% to $2.6 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Immunogen Inc. reported adjusted net income of 28 cents per share. By that measure, the company missed the mean analyst estimate of $-0.25. It missed the average revenue estimate of $6.02 million.

Quoting Management: “We expect 2013 to be a very important year for ImmunoGen,” commented Daniel Junius, President and CEO. “Roche is anticipating the approval of T-DM1 in the US early this year followed by approval in Europe later in 2013. We believe the launch of T-DM1 will be momentous for appropriate patients, their families, and their physicians. It will also mark the start of ImmunoGen earning what we believe will be a significant royalty stream.”

Key Stats:

Revenue decreased 36.43% from $4.09 million in the previous quarter. Net loss decreased 3.14% from $25.19 million in the previous quarter.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials.)